mpathic logo

mpathic

mpathic.ai

mpathic provides expert-led evaluation and benchmarking services for AI models, focusing on psychosocial risks such as mental health and misinformation. Its platform uses licensed clinicians to assess and calibrate AI behavior in high-risk scenarios, delivering model-ready insights for AI builders, enterprise organizations, and healthcare operators. The organization aims to build safer AI grounded in behavioral science and clinical standards.

Facts

HQ
Bellevue, WA, US
Sectors
Technology, Information and Internet
Founded
2021
Employees
51
Stage
Seed

Is this your organization? Claim it

mpathic releases mPACT Misinformation Benchmark v1: six AI models rarely ask questions and harmful replies persist

mpathic released the mPACT Misinformation Benchmark v1, which evaluated six leading AI models across multi-turn conversations and found that only 2% of responses asked about the user’s circumstances and 89% of harmful replies were followed by another harmful reply. The benchmark uses a behavioral-science framework to measure whether models help users reason through questionable beliefs, whether they reinforce harm, and whether they recover once conversations turn harmful.

Utah’s OAIP Taps Clinician-Led mpathic to Independently Evaluate Healthcare AI, Offer 'mpathic Verified' Certification

Utah’s Office of Artificial Intelligence Policy has agreed with clinician-founded mpathic to provide independent, clinician-led evaluations and ongoing audits of healthcare AI systems entering the state’s regulatory sandbox, including interdisciplinary reviews, clinical red teaming, and conversation-log assessments. Systems that pass may receive an mpathic Verified certification that OAIP accepts as evidence, while OAIP retains final authority over sandbox admission.

mpathic AI releases mPACT Eating Disorders Benchmark v1 to measure LLM risks in ED-related health chats

The mPACT Eating Disorders Benchmark v1 evaluates how well large language models identify and respond to eating-disorder risk in AI health conversations, addressing acute harms where models may inadvertently promote harmful behaviors or normalize dangerous beliefs. It is one of three clinically grounded mPACT benchmarks designed to provide domain-specific evaluation for high-stakes mental health interactions.

mpathic launches mPACT clinician-led benchmark; finds Claude, ChatGPT, Gemini avoid harm but lack consistent clinical support

mpathic launched mPACT, a clinician-led benchmark that evaluates how top AI chatbots handle high-risk conversations like suicide risk, eating disorders, and misinformation. Early results show leading models (Claude, ChatGPT, Gemini) generally avoid harmful responses but provide uneven clinical support and need improvement handling high-risk scenarios.

mpathic’s CBO Danielle Schlosser: Human-centered AI Means Prioritizing Well‑Being, Not Just User Preference

Danielle Schlosser argues that truly human-centered AI must prioritize people’s long-term well-being over short-term preferences, moving beyond training on immediate user likes to evaluate psychological impact, patterns over time, and human outcomes. mpathic pursues this approach with science-backed models, clinician expertise, and high-quality datasets to keep people safer and better off when using AI.

mpathic expands clinician-built safety services to foundational model developers and LLM apps, cites 5× Q4 growth and >70% reduction in unsafe responses

mpathic, a clinician-founded AI safety company, is expanding its clinically grounded safeguards to foundational model developers and LLM application teams to address high-risk uses like youth, mental health, and medical interactions, claiming 5x quarter-over-quarter growth and a >70% reduction in undesired model responses in an early engagement.

mpathic AI Highlights How Conversation Intelligence Improves Clinical Communication, ROI, and Equity

mpathic’s Xtalks webinar gathered clinical leaders and AI experts to show how conversation intelligence turns patient–provider dialogue into actionable insights that improve communication, consistency, and outcomes across health systems. Speakers highlighted real-time coaching, ethical implementation, ROI from better communication, and use cases like standardizing behaviors, protocol adherence, and reducing bias.

mpathic CEO Dr. Grin Lord Says AI Conversation Analytics Achieved PMF in Psychedelic Trials but $6B TAM Prompted Strategic Expansion

Dr. Grin Lord explains that mpathic found product-market fit with its AI conversation analytics—especially in psychedelic medicine trials where it automates review of patient recordings—but faced limits to venture-scale growth from a ~$6B TAM and chose to expand into adjacent clinical-trial markets informed by customer feedback.

mpathic’s mTrial platform speeds biopharma R&D by improving recruitment, retention, monitoring, and feedback

mTrial, mpathic’s quality-assurance platform, claims to speed biopharma R&D by optimizing patient recruitment and retention, reducing dropouts, automating monitoring, and delivering just-in-time feedback to enable faster, data-driven trial decisions. The platform aims to shorten timelines and improve trial outcomes by providing sponsor-defined candidate matching and actionable insights that lower manual oversight.

People

See all 5
  • Danielle Schlosser
    Danielle Schlosser Co-founder & Chief Business Officer
  • Grin Lord
    Grin Lord Founder - CEO and CEO – Founder
  • Alison Cerezo Executive, Chief Science Officer

Online